Key result
Aortic valve replacement with the 3f bioprosthesis demonstrated favorable early hemodynamics, with a 2-year mean transvalvular gradient of 8.8 mm Hg and no valve-related deaths.
Why the study?
Does the 3f bioprosthesis provide favorable hemodynamics and safety in patients undergoing aortic valve replacement?
Observational (n=46)
Does the 3f bioprosthesis provide favorable hemodynamics and safety in patients undergoing aortic valve replacement?
The 3f equine pericardial stentless bioprosthesis demonstrates favorable early hemodynamics and safety for aortic valve replacement.
Stentless aortic bioprostheses have been successfully used for over a decade. The 3f bioprosthesis is a new equine pericardial stentless valve, unique in its tubular design, preserving the native aortic sinuses post-implant. Forty-six consecutive aortic valve replacements with the 3f bioprosthesis were performed between June 2003 and January 2005. The patients were prospectively assessed and echocardiography was performed at 6 months, 12 months, and annually thereafter. The median follow-up was 2.1 + or - 0.9 years. There was one early and 4 late deaths; none were valve-related. The 2-year mean transvalvular gradient was 8.8 + or - 3.8 mm Hg, the mean echocardiographic aortic regurgitation grade was 0.4 + or - 0.7 (grade 1 being trivial). Echocardiographic sizing of the aortic annulus before surgery accurately predicted prosthesis size. The 3f bioprosthesis is easy to implant. Early clinical results are favorable, with hemodynamic profiles consistent with those of other stentless prostheses. Longer follow-up is required to confirm its durability.
No takes yet. Share an insight, caveat, or question.
Pillai et al. (2010) conducted an observational in Aortic valve disease requiring replacement (n=46). 3f bioprosthesis was evaluated on Clinical and echocardiographic outcomes (deaths, transvalvular gradient, aortic regurgitation). Aortic valve replacement with the 3f bioprosthesis demonstrated favorable early hemodynamics, with a 2-year mean transvalvular gradient of 8.8 mm Hg and no valve-related deaths.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: